Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline andKlebsiella pneumoniae | Zendy

Marilena Tsala | Zendy; Sophia Vourli | Zendy; George L. Daikos | Zendy; Athanassios Tsakris | Zendy; Loukia Zerva | Zendy; Johan W. Mouton | Zendy; Joseph Meletiadis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline andKlebsiella pneumoniae

Author(s) -

Marilena Tsala,

Sophia Vourli,

George L. Daikos,

Athanassios Tsakris,

Loukia Zerva,

Johan W. Mouton,

Joseph Meletiadis

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw354

Subject(s) - tigecycline , klebsiella pneumoniae , microbiology and biotechnology , pharmacodynamics , klebsiella pneumonia , pharmacokinetics , biology , antibiotics , minimum inhibitory concentration , medicine , pharmacology , bacteria , escherichia coli , pseudomonas aeruginosa , biochemistry , genetics , gene

In the absence of other therapeutic options, tigecycline is used to treat bloodstream infections and pneumonia caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp). In this study, the standard and high tigecycline dosing regimens were simulated and tested against different inocula of CP-Kp isolates in an in vitro pharmacokinetic (PK)/pharmacodynamic (PD) model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research